Shire
Clinical trials sponsored by Shire, explained in plain language.
A global biopharmaceutical company focused on rare diseases and specialty medicines, now part of Takeda.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Small study checks safety of fabry drug replagal in indian patients
Disease control Recruiting nowThis study is testing the safety of Replagal, an enzyme replacement therapy, in 5 Indian children and adults with Fabry disease who have not taken it before. Participants receive an infusion every 2 weeks for about a year. The main goal is to track side effects and serious reacti…
Phase 4 • Sponsor: Shire • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Massive global registry launched to unlock secrets of gaucher disease
Knowledge-focused Recruiting nowThis study is a long-term registry that follows over 1,200 people with Gaucher disease worldwide. It collects real-world data on how the disease progresses and how different treatments, including velaglucerase alfa, work over time. No new drugs are being tested; instead, particip…
Sponsor: Shire • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC